Activism Snapshot
WisdomTree (WT) won their proxy contest with ETFS Capital according to their press release on the 12th. They have not yet released the 8-K with actual voting tallies, so we’ll have to wait to see just how much support WT ended up getting. Both Glass Lewis and ISS had supported the board’s nominees. ETFS Capital had tired to make the point that governance and results would be even worse had they not already pushed WT to make improvements.
AmeriServ Financial (ASRV) entered into a cooperation and settlement agreement with Driver Opportunity Partners. AmeriServ Financial is repurchasing Drivier’s shares for an aggregate of $1,494,647 while Driver has agreed to drop its lawsuit for a settlement amount equal to $1,762,659. Driver also is dropping its plans to nominate 3 directors to the board.
Forte Biosciences (FBRX) entered into a Standstill and Voting agreement with Camac Capital. Camac will get board seats and the board will create a new committee focused on assessing strategic alternatives.
Medallion (MFIN) won its fight with ZimCal as ~77% of shareholders supported the board’s two nominees Robert Meyer and David Rubnick. Shareholders also supported Say-On-Pay with approximately 74% voting FOR.
Braemer Hotels (BHR) and Blackwells continue to trade blows. BHR just released the proxy filing for the meeting and has set the date for July 30th. So we have over a month of additional back and forth to come.
Enhabit (EHAB) and Masimo (MASI) also released their contested proxies and both selected July 25th for their shareholder meeting dates. EHAB is down almost -30% in the past year and MASI is down over -15%, so unless some dramatic change occurs in the next 45 days, both will have uphill battles to convince shareholders that they’ve got the right plans and teams to turn the ship around. LL Flooring (LL) is in an even worse position with it now down more than 65% this year alone and 94% over the past three years.
Latest Activism and Governance research from Boardroom Alpha:
ACTIVISM UPDATE
LATEST 13-D FILINGS
LATEST PROXY CONTEST FILINGS
TICKER |
COMPANY |
TSR 1/3yr |
MEETING DATE |
LATEST PROXY |
SUMMARY |
TARGET FILINGS |
ACTIVIST FILINGS |
BHR |
BRAEMAR HOTELS & RESORTS INC |
-24.5%
-50.5% |
Jul 30 |
2024-06-17 – DEFC14A |
- Nominating four directors: Michael Cricenti, Jennifer M. Hill, Betsy L. McCoy and Steven J. Pully
- Proposal to remove “overreaching” advance notice bylaw provision
- Proposal to urge the Board to amend the Bylaws to preclude any current or former employee, director, officer, or control person of the Corporation or Ashford (as defined in the Proxy Statement) and Ashford’s affiliates from serving as the Corporation’s chairman of the Board
- Proposal to require the Board to disclose all extraordinary transaction proposals made by stockholders, affiliates and third parties during the two most recently completed calendar years and the terms of those proposed transactions
- Proposal to require the Board to disclose all compensation paid by the Corporation to members of the Bennett family, The Dallas Express and employees, directors or agents of The Dallas Express, including Louis Darrouzet
|
BRAEMAR HOTELS & RESORTS INC
Jun 17 – DEFC14A
Jun 14 – DEFA14A
Jun 13 – DEFA14A
Jun 12 – DEFA14A
Jun 11 – DEFA14A
May 23 – DEFA14A
May 22 – DEFA14A
May 22 – DEFA14A
May 21 – DEFA14A
May 20 – DEFA14A |
BLACKWELLS CAPITAL LLC
Jun 14 – DFAN14A
Jun 13 – DFAN14A
Jun 12 – DFAN14A
Jun 11 – DFAN14A
Jun 10 – DFAN14A
May 20 – DFAN14A
May 17 – DFAN14A
May 16 – DFAN14A
May 16 – DFAN14A
May 13 – DFAN14A |
EHAB |
ENHABIT INC |
-29.1% |
Jul 25 |
2024-06-11 – DEFC14A |
- AREX Capital owns 4.8% of the shares of Enhabit (EHAB)
- AREX Capital believes EHAB strategic review should have resulted in a sale of the company.
- AREX Capital believes EHAB board lacks “Health and Hospice” expertise
- AREX nominating 7 directors to the board: Megan Ambers, James T. Corcoran, Maxine Hochhauser, Mark W. Ohlendorf, Anna-Gene O’Neal, Dr. Gregory S. Sheff, Juan Vallarino.
|
ENHABIT INC
Jun 12 – DEFA14A
Jun 11 – DEFA14A
Jun 10 – DEFC14A
Jun 10 – DEFA14A
May 23 – PREC14A
May 23 – DEFA14A |
AREX CAPITAL MANAGEMENT, LP
Jun 11 – DFAN14A
Jun 11 – DEFC14A
Jun 10 – PRRN14A
May 29 – DFAN14A
May 28 – PREC14A
May 09 – DFAN14A |
LL |
LL FLOORING HOLDINGS INC |
-69.0%
-93.6% |
Jul 10 |
2024-05-31 – DEFC14A |
- Seeking to elect 4 directors: Thomas D. Sullivan, John Jason Delves and Jill Witter
- Recommending voting “WITHHOLD” for company nominees: Douglas T. Moore, Ashish Parmer and Nancy M. Taylor
- F9 group includes Mr. Sullivan who founded the company in 1994 and served as Chair through 1994
- F9 previously made a bid to acquire the company for $5.76 per share — a 100% premium to the then 52-week low of $2.75
|
LL FLOORING HOLDINGS INC
Jun 11 – DEFA14A
Jun 11 – DEFA14A
Jun 07 – DEFA14A
Jun 05 – DEFA14A
Jun 03 – DEFA14A
Jun 03 – DEFA14A
Jun 03 – DEFA14A
May 31 – DEFA14A
May 24 – DEFC14A
May 20 – PREC14A |
F9 INVESTMENTS LLC
Jun 14 – DFAN14A
Jun 13 – DFAN14A
Jun 07 – DFAN14A
Jun 03 – DFAN14A
Jun 03 – DFAN14A
May 31 – DFAN14A
May 31 – DEFC14A
May 28 – PRRN14A
May 20 – PREC14A |
MASI |
MASIMO CORP |
-15.2%
-38.9% |
Jul 25 |
2024-06-17 – DEFC14A |
- Politan Capital, owning ~9% of MASI, has nominated two directors to the board of Masimo
- Politan Capital previously won two board seats at last year’s shareholder meeting
- Politan has nominated William Jellison, former CFO of Stryker and Darlene Solomon, former CTO of Agilent Technologies
- Politan paints a picture (see their filings) of MASI being uncooperative and freezing their board members out
- Masimo (see their filings) refutes Politan’s claims
|
MASIMO CORP
Jun 17 – DEFA14A
Jun 17 – DEFC14A
Jun 12 – DEFA14A
May 31 – PREC14A
May 31 – DEFA14A
May 31 – DEFA14A
May 20 – DEFA14A
May 16 – DEFA14A
May 13 – DEFA14A
May 13 – DEFA14A |
POLITAN CAPITAL MANAGEMENT LP
Jun 14 – PRRN14A
Jun 03 – PREC14A
Jun 03 – DFAN14A
May 10 – DFAN14A
Mar 25 – DFAN14A |
MRC |
MRC GLOBAL INC |
20.4%
11.2% |
TBD |
|
- Nominating two directors to the board: Brad Favreau and Daniel Silvers
- Engine Capital believes that MRC is significantly underperforming, especially relative to DNOW Inc.
- Engine Capital believes that MRC’s inability to settle it’s ongoing dispute with Cornell Capital is preventing MRC from optimizing capital structure
- Engine Capital believes that MRC’s M&A strategy is flawed and that CEO Rob Saltiel does not have a successful track record in acquisitions or integrations
|
MRC GLOBAL INC
Apr 02 – DEFA14A |
ENGINE CAPITAL, L.P. |
NVAX |
NOVAVAX INC |
79.1%
-93.1% |
TBD |
2024-05-06 – PREC14A |
- Shah Capital Management intends to vote against Novavax directors Richard H. Douglas, Margaret G. McGlynn, and David Mott
- Shah Capital Management believes that Novavax is undervalued and continues to suffer from poor profitability, despite the substantial value to be unlocked in the Company’s Matrix-M adjuvant platform and non-mRNA protein vaccine portfolio.
- Shah Capital Management met with management and the board multiple times over the course of 2023 and 2024, but believes Novavax has been unresponsive to their suggestions.
|
NOVAVAX INC
Jun 05 – DEFA14A
Apr 29 – DEFA14A |
SHAH CAPITAL MANAGEMENT
May 20 – DFAN14A
May 13 – DFAN14A
May 08 – DFAN14A
May 07 – DFAN14A
May 06 – PREC14A
May 06 – DFAN14A |
SLRX |
SALARIUS PHARMACEUTICALS INC |
-75.5%
-98.6% |
TBD |
|
- Mismanagement and Poor Performance: The letter claims that Salarius Pharmaceuticals is mismanaged by its current Board and management, leading to a significant decline in shareholder value and underperformance of the company.
- Compensation Issues: The letter criticizes the Board for failing to establish a culture of accountability, highlighting excessive and poorly justified salary increases and stock option grants to executives despite the company’s poor performance and declining stock price.
- Misaligned Incentives: The author points out that the Board members and executives hold a minimal percentage of the company’s shares and have not made open market purchases, indicating a lack of alignment with shareholder interests.
- Questionable Decisions and Lack of Transparency: The letter accuses the Board of engaging in “curious compensation practices” and “disclosure diffusion,” making it difficult for shareholders to get a clear understanding of executive compensation and undermining informed voting.
- Call for Change: The activist argues for the need for new Board members with fresh perspectives and better alignment with shareholder interests, expressing a lack of confidence in the current Board’s ability to improve the company’s performance and accountability.
|
SALARIUS PHARMACEUTICALS INC
Mar 26 – DEFA14A |
ELVIN LEE
Mar 20 – DFAN14A |
SPRU |
SPRUCE POWER HOLDING CORP |
-49.8%
-95.2% |
TBD |
2024-04-17 – PREC14A |
- Clayton Partners, JSCC Family Trust, and Jason Stankowski are contesting the proxy
- Clayton is nominating Jason Stankowski and Clara Nagy McBane to the board
- Clayton believes the company is not being managed to the benefit of its shareholders — believes “Spruce is, at worst, a break-even business and has significant opportunities for positive cash flow generation going forward”
- Clayton disagrees with the company not buying back any stock despite trading at a 25% discount to the estimated value of the stock
|
SPRUCE POWER HOLDING CORP |
CLAYTON PARTNERS LLC
May 31 – PRRN14A
Apr 18 – DFAN14A
Apr 17 – PREC14A |
RECENT COOPERATION AGREEMENTS
TARGET |
1-Year TSR |
ACTIVIST |
SUMMARY |
FILING |
DATE |
STOCK CHANGE |
DAYS SINCE |
AMERISERV FINANCIAL INC (ASRV) |
-5.2% |
Driver Management Co LLC |
- Driver agreed to withdraw its notice of intent to nominate three directors at the upcoming shareholder meeting.
- Driver agreed to drop their lawsuits filed against AmeriServ for a settlement fee of $1,762,659.
- AmeriServ agreed to repurchase 628,003 shares from Driver at a total cost of $1,494,647.
|
View Filing |
2024-06-13 |
4.6% |
4 |
FORTE BIOSCIENCES INC (FBRX) |
-45.2% |
Camac Fund, LP |
- The FBRX board will expand to nine seats. One incumbent director will resign and two directors will be selected from a Camac list of five options.
- The FBRX board will create a committee to explore strategic altenratives for the company.
- Camac and FBRX will settle their legal case.
- The agreement runs through the 2028 annual shareholder meeting.
- As of the agreement date, Camac held 3.5% of FBRX’s outstanding stock.
|
View Filing |
2024-06-11 |
1.6% |
6 |
ANIKA THERAPEUTICS INC (ANIK) |
-3.9% |
Caligan Partners LP |
- Increasing board to 10 directors
- Appointing William Jellison as an independent Class I director (2024) and Joseph Capper as an independent Class II (2025)
- Board will nominate and support Jellison at 2024 annual meeting
- Mr. Jellison and Mr. Capper will be appointed to the Capital Allocation Committee
- Board size will decrease to 9 directors at 2024 annual meeting
- Company agreed to implement a share repurchase program
|
View Filing |
2024-05-28 |
6.1% |
20 |
RECENT PROXY CONTEST RESOLUTIONS
TICKER |
COMPANY |
MEETING DATE |
RESULTS |
ACTIVIST SITUATION SUMMARY |
MFIN |
MEDALLION FINANCIAL CORP |
Jun 11 |
- Medallion Financial won this fight with shareholders electing the board’s two nominees with ~77% of the vote.
- Shareholders also supported the board’s executive compensation plan via the Say-on-Pay vote at ~74% support.
|
- ZimCal looking to add Stephen Hodges and Judd Deppisch to the board
- ZimCal flags long-term underperformance with Medallion down 40% over the last 10 years and heightened near-term risk from subprime exposure
- ZimCal has published a site supporting its case at: https://restoretheshine.com/
|
WT |
WISDOMTREE INC |
Jun 12 |
- WisdomTree, Inc. (WT) released a press release on June 12th announcing that all nine WT nominees were elected.
- WT said “Voters repudiate ETFS Capital And Graham Tuckwell”
- WT also said all other proposals, including say-on-pay for the year and say-on-pay frequency passed.
- The 8-k with certified results will help provide better insights into the actual support levels as there is no mention in the press release.
|
- ETFS Capital owns approximately 10% of Wisdom Tree (WT) and believes “immediate action to unlock significant value for all stockholders and halt further value destruction.”
- Puts a focus on WT’s strategy of transitioning to a decentralized finance (DeFi) business and believes that it resulted in poor management of the core, profitable ETF business.
- Believes the company’s true value lies in its ETF business, which suffers from poor profitability despite record assets under management.
- Believes its attempts to be collaborative have been met with ” a public and bafflingly hostile response.”
|